BioMarin Pharmaceutical Inc.
BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPSā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$58.51
Price-0.95%
-$0.56
1Y
Price
Market Cap
$11.253b
Large
Price/Earnings 3y Avg5y Avg
32.5x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-0.5%
EBITDA Margin-5.3%
Net Profit Margin+6.7%
Free Cash Flow Margin-0.5%
EBITDA Margin-5.3%
Net Profit Margin+6.7%
Free Cash Flow MarginRevenue
$3.221b
+12.9%
1y CAGR+15.4%
3y CAGR+15.0%
5y CAGREarnings
$348.901m
-18.3%
1y CAGR+51.6%
3y CAGR+118.9%
5y CAGREPS
$1.80
-18.5%
1y CAGR+50.0%
3y CAGR+116.0%
5y CAGRBook Value
$6.087b
$7.594b
Assets$1.507b
Liabilities$642.873m
DebtDebt to Assets
8.5%
1.1x
Debt to EBITDAFree Cash Flow
$724.956m
+52.5%
1y CAGR+242.1%
3y CAGR+164.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company